Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (191-200 of 339) with videos related to

Pageof 34
Sort By:
Oncotarget|July 3, 2018
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literatureAndrea Kuendgen, Catharina Müller-Thomas, Michael Lauseker, et al.
Clinical Chemistry and Laboratory Medicine|April 22, 2005
Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profilingManuel Aivado, Dimitrios Spentzos, Gil Alterovitz, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Haematologica|June 1, 2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-TrialThomas Schroeder, Matthias Stelljes, Maximilian Christopeit, et al.
Annals of Hematology|March 24, 2005
Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II studyAristoteles A N Giagounidis, Sabine Haase, Ulrich Germing, et al.
Haematologica|October 14, 2011
Therapy-related myeloid neoplasms following treatment with radioiodineThomas Schroeder, Andrea Kuendgen, Sabine Kayser, et al.
Annals of Hematology|April 9, 2026
Impact of early tacrolimus exposure on outcomes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromesPaul Jäger, Andreas Alexander Ralfs, Felicitas Schulz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring systemJulie Schanz, Christian Steidl, Christa Fonatsch, et al.
Annals of Hematology|January 12, 2023
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST studyUlrich Germing, Pierre Fenaux, Uwe Platzbecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study groupVerena I Gaidzik, Peter Paschka, Daniela Späth, et al.
Pageof 34

Showing results (191-200 of 339) with videos related to

Sort By:
Pageof 34
Oncotarget|July 3, 2018
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literatureAndrea Kuendgen, Catharina Müller-Thomas, Michael Lauseker, et al.
Clinical Chemistry and Laboratory Medicine|April 22, 2005
Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profilingManuel Aivado, Dimitrios Spentzos, Gil Alterovitz, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Haematologica|June 1, 2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-TrialThomas Schroeder, Matthias Stelljes, Maximilian Christopeit, et al.
Annals of Hematology|March 24, 2005
Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II studyAristoteles A N Giagounidis, Sabine Haase, Ulrich Germing, et al.
Haematologica|October 14, 2011
Therapy-related myeloid neoplasms following treatment with radioiodineThomas Schroeder, Andrea Kuendgen, Sabine Kayser, et al.
Annals of Hematology|April 9, 2026
Impact of early tacrolimus exposure on outcomes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromesPaul Jäger, Andreas Alexander Ralfs, Felicitas Schulz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring systemJulie Schanz, Christian Steidl, Christa Fonatsch, et al.
Annals of Hematology|January 12, 2023
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST studyUlrich Germing, Pierre Fenaux, Uwe Platzbecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study groupVerena I Gaidzik, Peter Paschka, Daniela Späth, et al.
Pageof 34